Arsenic trioxide as a treatment for myelodysplastic syndrome

Current Hematologic Malignancy Reports

Volumn 1, Issue 1, 2006, Pages 34-38

  Sekeres, Mikkael A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ARSENIC TRIOXIDE; ASCORBIC ACID; CYTARABINE; DEXAMETHASONE; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; GLUTATHIONE; GROWTH FACTOR; MEVINOLIN; THALIDOMIDE; VALPROIC ACID;

BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FLUID RETENTION; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL NEUROPATHY; PROMYELOCYTIC LEUKEMIA; PRURITUS; REVIEW; SEPSIS; SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CLINICAL TRIALS AS TOPIC; DNA-BINDING PROTEINS; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; OXIDES; PROTO-ONCOGENES; SALVAGE THERAPY; THALIDOMIDE; TRANSCRIPTION FACTORS;

EID: 33750308054     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-006-0015-6     Document Type: Review

References (44)

1. Cheson BD, Bennett JM, Kantarjian H, et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674. The standard for clinical trial response criteria in myelodysplastic syndrome.
2. Silverman L: The myelodysplastic syndrome. In Cancer Medicine. Edited by Holland J, Frei E, Bast R, et al. Baltimore, Maryland: Williams and Wilkins; 1996:2593-2615.
3. Economopoulos T, Stathakis N, Foudoulakis A, et al.: Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur J Haematol 1987, 38:338-344.
4. Foucar K, Langdon RM, Armitage JO, et al.: Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985, 56:553-561.
5. Kerkhofs H, Hermans J, Haak HL, et al.: Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 1987, 65:73-81.
6. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999, 10:1419-1432.
7. Vallespi T, Torrabadella M, Julia A, et al.: Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985, 61:83-92.
8. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
9. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. The most widely accepted prognostic system in myelodysplastic syndrome, based on an analysis of 816 patients.
10. Anderson JE, Appelbaum FR, Fisher LD, et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82:677-681.
11. Bunin NJ, Casper JT, Chitambar C, et al.: Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol 1988, 6:1851-1855.
12. Kernan NA, Bartsch G, Ash RC, et al.: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993, 328:593-602.
13. Aul C, Gattermann N, Schneider W: Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992, 82:358-367.
14. Schipperus M, Sonneveld P, Lindemans J, et al.: The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. Leukemia 1990, 4:267-272.
15. Allampallam K, Shetty V, Mundle S, et al.: Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002, 75:289-297.
16. Sugimoto K, Hirano N, Toyoshima H, et al.: Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993, 81:3022-3026.
17. Boudard D, Vasselon C, Bertheas MF, et al.: Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002, 70:115-125.
18. Invernizzi R, Pecci A, Bellotti L, et al.: Expression of p53, bcl-2, and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma 2001, 42:481-489.
19. Parker JE, Mufti GJ, Rasool F, et al.: The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000, 96:3932-3938.
20. Klaassen C: Heavy metals and heavy metal antagonists. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. Edited by Hardman J, Gilman A, Limbird L. New York: McGraw-Hill; 1996:1649-1672.
21. Miller WH, Jr, Schipper HM, Lee JS, et al.: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
22. Shen ZX, Chen GQ, Ni JH, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
23. Sun H, Ma L, Hu X, et al.: Treatment of acute promyelocytic leukemia by Ailing-1 therapy with use of syndrome differentiation by traditional Chinese medicine. Chin J Comb Trad Chin Med West Med 1992, 12:170-171.
24. Zhang P, Wang S, Hu X: Arsenic triozide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996, 17:58-62.
25. Chen GQ, Shi XG, Tang W, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
26. Chen GQ, Zhu J, Shi XG, et al.: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
27. Roboz GJ, Dias S, Lam G, et al.: Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
28. Soignet SL, Maslak P, Wang ZG, et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348. This study demonstrated the ability of arsenic trioxide to induce remission in patients with relapsed leukemia.
29. Soignet SL, Frankel SR, Douer D, et al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
30. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development studies. Oncologist 2001, 6(Suppl 2):22-28.
31. Munshi NC, Tricot G, Desikan R, et al.: Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002, 16:1835-1837.
32. Hussein MA, Saleh M, Ravandi F, et al.: Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 2004, 125:470-476.
33. Rousselot P, Larghero J, Arnulf B, et al.: A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004, 18:1518-1521.
34. Vey N, Dreyfus F, Guerci A, et al.: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary results of a phase 1/2 study [abstract]. Blood 2003, 102:422a (Abstract 1536). One of the largest trials of ATO as monotherapy in patients with MDS.
35. List AF, Schiller GJ, Mason J, et al.: Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase 2 clinical study [abstract]. Blood 2003, 102:423a (Abstract 1539). One of ATO largest trials of ATO as monotherapy in patients with MDS.
36. Cheson BD, Bennett JM, Kantarjian H, et al.: Myelodysplastic syndromes standardized response criteria: further definition [letter]. Blood 2001, 98:1985.
37. Corral LG, Kaplan G: Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999, 58:107-113.
38. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
39. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996, 31:213-221.
40. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999, 5:582-585.
41. Raza A, Buonamici S, Lisak L, et al.: Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 2004, 28:791-803. The only published combination trial of ATO for patients with MDS. Also defines the EVI1 subgroup who may in particular derive benefit from this combination.
42. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al.: Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002, 8:3658-3668.
43. Grad JM, Bahlis NJ, Reis I, et al.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001, 98:805-813.
44. Hussein M: A Phase 2 trial evaluating triple combination therapy with trisenox, ascorbic acid, and dexamethasone (TAD regimen) in multiple myeloma. Paper presented at the Eighth Congress of the European Hematology Association. Lyon, France, June 13-15, 2003.